Navigation Links
GSW Launches Multi-Channel Detailing Platform and Expands Closed-Loop Marketing Suite
Date:12/11/2013

ectiveness and usage of the detail regardless of the channel in which it was delivered.

In addition to the new iQ.mercury 3 platform, GSW already offers two closed-loop marketing (CLM) applications for marketers who want to manage and evaluate campaign feedback as they communicate with the marketplace. 

iQ.align is an easy-to-use analytics dashboard and cloud-based survey planner that gives brand managers a communications platform with real-time feedback from their sales organization. Used by many top pharmaceutical brands, iQ.align collects important data from iQ.mercury and delivers metrics to an easy-to-use dashboard for gathering insights from the field. It is compatible with many customer relationship management platforms, offering flexibility to clients looking for CLM solutions. 

iQ.fileShare software gives brand managers the ability to send approved emails to physicians with the latest informational content about their brands.  From their iPads, sales reps can sync the latest versions of approved content and share supported resources with their contacts.  Brand managers can easily manage rep groups and resource files from a single cloud-based content management system.

Because the products are modular, clients have the option to purchase iQ.align, iQ.fileShare, and iQ.mercury components separately or together as a bundled CLM solution.

Beginning in December, GSW will host a series of training workshops and webinars for healthcare brands wishing to upgrade to the new platform.  For more information about iQ.mercury and closed-loop marketing applications, contact marketing manager Tyler Durbin at tyler.durbin@gsw-w.com or go to www.iqmercury.com and register to receive inf
'/>"/>

SOURCE GSW
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
3. Mylan Launches Generic Version of Zyprexa® Tablets
4. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
5. American Academy of Family Physicians Foundation Launches Cities for Life
6. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
7. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
8. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
9. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
10. Practice Fusion Launches API to Democratize Lab Integrations
11. Kmart® Launches New Pet Prescription Program And Purina® Treat Giveaway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Reportlinker.com announces that ... its catalogue: Acute Heart Failure Global ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart Failure ... Summary GlobalData,s clinical trial report, "Acute Heart ... data on the Acute Heart Failure clinical trial ...
(Date:9/2/2014)... 2, 2014    - ... muestran agentes antitrombóticos no utilizados óptimamente para prevenir ... Las presentaciones de GARFIELD-AF en el ESC CONGRESS ... los resultados de pacientes en riesgo de sufrir ... Los datos de casi 12.500 pacientes ...
(Date:9/2/2014)... , -- GARFIELD-AF ... into treatment and outcomes of patients at risk ... Data from nearly 12,500 patients enrolled ... Fibrillation (GARFIELD-AF), an innovative, independent academic research initiative, ... fibrillation (AF) patients remain sub-optimal despite the transition ...
Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... Solutions Development Company (MSDC), a drug discovery and ... metabolic diseases, announced today that it has launched ... second drug candidate for the treatment of type ... placebo-controlled clinical trial will involve approximately 125 patients ...
... SAN and NYSE: SNY ) announced today ... Rights (CVRs) offered to Genzyme shareholders as part of ... by the U.S. Securities and Exchange Commission. ... Genzyme, sanofi-aventis has commenced an exchange offer to acquire ...
Cached Medicine Technology:Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 3
(Date:9/2/2014)... -- Complications are rare among breast cancer patients ... indicates. However, the researchers did find that ... higher risk for certain complications than a single ... breast cancer patients who had a single (64 ... and were followed for 30 days after surgery. ...
(Date:9/2/2014)... their own spread throughout the body by coaxing cells ... to a new report by Johns Hopkins scientists. , ... Communications , the researchers describe animal and cell-culture experiments ... by breast cancer cells. These molecules cause lymphatic endothelial ... produce proteins called CCL5 and VEGF. CCL5 attracts tumor ...
(Date:9/2/2014)... (PRWEB) September 03, 2014 Operators in ... to millions of people annually, arranging care and counsel ... and private enterprises are expected to derive $39.4 billion ... donations and private income. Over the five years through ... annualised rate of 6.6%, including growth of 4.1% in ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Melatonin supplements did not ... fractures, a new study found. Many older hospital ... due to disruption of their normal sleep-wake cycle. A ... that contributes to delirium, but there has been little ... This study included 378 patients, average age 84, ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... the Ebola outbreak continues to overwhelm health-care workers in ... States and the United Nations called on Tuesday for ... of the often-fatal virus. Dr. Thomas Frieden, director ... said that without a greater global commitment in resources ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3
... screening program to detect peripheral arterial disease (PAD) on time ... For Life? this program can help detect the onset of ... of having an amputation by half. // ... affects every vascular bed in the body and it increases ...
... has the remarkable ability to discriminate between self and ... immune system, the human body would have lost its ... // ,The immune system produces certain substances ... cells, effectively labeling them as "bad" so that other ...
... Baptist Medical Center certain herbs and dietary supplements can ... other gastrointestinal problems.// ,The researcher Kemper, had ... were out there doing, and came up with a ... historically, 50 years ago, people used home remedies. Then ...
... unusual antibiotics that have the potential to be effective ... at the 230th national meeting of the American Chemical ... ,The new antibiotics are synthetic forms of cephalosporin, a ... kill bacteria by masquerading as components of the bacterial ...
... a research team led by the National Human Genome ... experimental anti-cancer drugs also shows promise in laboratory studies ... aging. // ,These drugs belong to a ... tested in people with myeloid leukemia, neurofibromatosis and other ...
... loss of interest in eating during old age is the ... a plan which will help older people eat nutritious food ... ,Doctors at the institute advise that High fibre in ... can help fight diabetes, heart disease and diverticulosis. Folic acid ...
Cached Medicine News:Health News:Diabetic Amputation May Reduce If Free Screenings Are There 2Health News:Fighting against disease as easy as eating eggs 2Health News:Atypical Antibiotics For Super Bugs 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: